Publication date: Jul 11, 2023
Indolent B-cell non-Hodgkin lymphoma (B-iNHL) is a group of mature B-cell lymphomas that develop slowly. It is characterized by low immune function and could be risky when complicated with novel coronavirus infection (COVID-19). In order to guide the prevention and treatment of B-iNHL combined with COVID-19, China Anti-Cancer Association Hematological malignancies Committee, the Chinese Society of Hematology Medical Association and Chinese Chronic lymphoproliferative Diseases Working Group formed consensus on COVID-19 vaccination, prognosis, treatment and follow-up of B-iNHL patients for clinician reference.
| Concepts | Keywords |
|---|---|
| Cancer | Cell |
| China | Chinese |
| Covid | Consensus |
| Indolent | Coronavirus |
| Vaccination | Covid |
| Group | |
| Hodgkin | |
| Indolent | |
| Infection | |
| Inhl | |
| Lymphoma | |
| Non | |
| Prevention | |
| Treatment |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | coronavirus infection |
| disease | MESH | B-cell lymphomas |
| disease | MESH | COVID-19 |
| disease | MESH | Cancer |
| disease | MESH | Hematological malignancies |
| disease | VO | vaccination |
Original Article
(Visited 4 times, 1 visits today)